Spotlight
Clinical Role
Clinical
Supplement Spotlight
CME/CE
Subscribe
Andrew L. Wilson, PharmD, FASHP, Vice President, McKesson 340B Solutions
Articles
Understanding and Navigating Specialty and Orphan Drug Challenges in the 340B Program
Lisa Nezneski, PharmD, BCPS, Managing Consultant, McKesson 340B Solutions;Christopher S. Shain, PharmD, BCPS, Assistant Vice President, McKesson 340B Solutions;Andrew L. Wilson, PharmD, FASHP, Vice President, McKesson 340B Solutions
March 15th 2019Failure to recognize the interests of manufacturers to ensure proper use of 340B pricing may result in 340B hospitals missing the opportunity to secure and retain discounts on key orphan and specialty drugs or may render them unable to access the drugs at all.
Read More
Latest Updated Articles
Published: June 11th 2024 | Updated: July 27th 2024
Balancing Trust and Technology: The Role of AI in Patient-Pharmacist Interactions
Published: June 11th 2024 | Updated: July 27th 2024
Addressing Disparities in AI-Driven Diagnostics: Ethical and Practical Implications
Published: July 23rd 2024 | Updated: July 27th 2024
VP Kamala Harris’s Policies and Stances on Health Care, Reproductive Rights Take Center Stage
Published: October 18th 2023 | Updated: July 27th 2024
Pharmacists Can Optimize Treatment for Patients with NASH, Decreasing Economic Burden
Published: July 23rd 2024 | Updated: July 27th 2024
Trivalent Influenza Vaccines Are Readied for Fall
Published: July 15th 2024 | Updated: July 27th 2024
Biosimilar Ranibizumab Could be More Cost-Effective Than Aflibercept for nAMD
